Indeed, patients with BD present altered levels of inflammatory markers such as interleukin 4 (IL-4), interleukin 1 receptor antagonist (IL-1Ra), or the soluble interleukin 6 receptor (sIL-6R), changes that reverted when adequate treatment for PD was administered [12,13]. The gene discussed is IL6R; the disease is Behcet disease.